Japanese encephalitis vaccine in travelers

Expert Review of Vaccines

Volumn 7, Issue 5, 2008, Pages 689-693

  Jelinek, Tomas ^a  

^a Berlin Center for Travel and Tropical Medicine   (Germany)

Author keywords

Japanese encephalitis; Traveler; Vaccine

Indexed keywords

CHIMERIVAX JE; IXIARO; JAPANESE ENCEPHALITIS VACCINE;

ALLERGY; BRAIN; DRUG SAFETY; ENDEMIC DISEASE; EPIDEMIC ENCEPHALITIS; HUMAN; IMMUNOGENICITY; INFECTION RISK; JAPANESE ENCEPHALITIS VIRUS; MOSQUITO; NEUROLOGIC DISEASE; NONHUMAN; PRIORITY JOURNAL; REVIEW; RURAL AREA; TRAVEL; VACCINE PRODUCTION; VERO CELL; VIRUS TRANSMISSION;

ANIMALS; CERCOPITHECUS AETHIOPS; ENCEPHALITIS, JAPANESE; HUMANS; JAPANESE ENCEPHALITIS VACCINES; MICE; TRAVEL; VACCINATION; VACCINES, INACTIVATED; VERO CELLS;

EID: 45849096079     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/14760584.7.5.689     Document Type: Review

References (45)

1. Japanese encephalitis. Inactivated Japanese encephalitis virus vaccine. Wkly Epidemiol. Rec. 69(16), 113-118 (1994).
2. Inactivated Japanese encephalitis virus vaccine. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb. Mortal. Wkly Rep. 42(RR-1), 1-15 (1993).
3. Igarashi A. Epidemiology and control of Japanese encephalitis. World Health Stat. Q. 45(2-3), 299-305 (1992).
4. Umenai T, Krzysko R, Bektimirov A, Assaad A. Japanese encephalitis: current worldwide status. Bull. World Health Organ. 63, 623-631 (1985).
5. Wong SC, Ooi MH, Abdullah AR et al. A decade of Japanese encephalitis surveillance in Sarawak, Malaysia: 1997-2006. Trop. Med. Int. Health 13, 52-55 (2008).
6. Kari K, Liu W, Gautama K et al. A hospital-based surveillance for Japanese encephalitis in Bali, Indonesia. BMC Med. 4, 8 (2006).
7. Bista MB, Shrestha JM. Epidemiological situation of Japanese encephalitis in Nepal. J. Nepal Med. Assoc. 44(158), 51-56 (2005).
8. Lam K, Tsang OT, Yung RW, Lau KK. Japanese encephalitis in Hong Kong. Hong Kong Med. J. 11, 182-188 (2005).
9. Monath T. Japanese encephalitis - a plague of the orient. New Engl. J. Med. 319, 641-643 (1988).
10. Okuno T. An epidemiological review of Japanese encephalitis. World Health Stat. Q. 3, 120-131 (1978).
11. Thogcharoen P. Japanese encephalitis virus encephalitis: an overview. Southeast Asian J. Trop. Med. Public Health 20, 559-573 (1989).
12. Rosen L. The natural history of Japanese encephalitis virus. Ann. Rev. Microbiol. 40, 395-414 (1986).
13. Sucharit S, Surathin K, Shrestha S. Vectors of Japanese encephalitis virus (JEV): species complexes of the vectors. Southeast Asian J. Trop. Med. Public Health 20, 611-621 (1989).
14. Hoke C, Nisalak A, Sangawhipa N et al. Protection against Japanese encephalitis by inactivated vaccines. N. Engl. J. Med. 319, 608-614 (1988).
15. Simpson TW, Meiklejohn G. Sequelae of Japanese B encephalitis. Am. J. Trop. Med. 27, 727-731 (1947).
16. Solomon T, Vaughn DW. Pathogenesis and clinical features of Japanese encephalitis and West Nile virus infections. Curr. Top. Microbiol. Immunol. 267, 171-194 (2002).
17. Solomon T. Control of Japanese encephalitis - within our grasp? N. Engl. J. Med. 355(9), 869-871 (2006).
18. Macdonald W, Tink A, Ouvrier R. Japanese encephalitis after a two-week holiday in Bali. Med. J. Aust. 150, 334-337 (1989).
19. Wittesjö B, Eitrem R, Niklasson B, Vene S, Mangiafico J. Japanese encephalitis after a 10-day holiday in Bali. Lancet 345, 856 (1995).
20. Tsarev SA, Sanders ML, Vaughn DW et al. Phylogenetic analysis suggests only one serotype of Japanese encephalitis virus. Vaccine 18(Suppl. 2), 36-43 (2000).
21. Oya A. Japanese encephalitis vaccine. Acta Pediatr. Jpn 30, 175-184 (1988).
22. Rojanasuphot S, Charoensuk O, Kityprayura D. A field trial of Japanese encephalitis virus vaccine produced in Thailand. Southeast Asian J. Trop. Med. Public Health 20, 653-654 (1989).
23. Rao Bhau L, Singh F, Gowal D. Safety and efficacy of Japanese encephalitis vaccine produced in India. Indian J. Med. Res. 88, 301-307 (1988).
24. Shepard D, Halstead S. Dengue. In: Disease Control Priorities in Developing Countries. Jamison DT, Mosley WH, Measham AR, Bobadilla JL (Eds). Oxford University Press, Inc., NY, USA 303-330 (1993).
25. Tsai T, Yu Y. Japanese encephalitis vaccines. In: Vaccines (2nd Edition). Plotkin S, Mortimer EJ (Eds). WB Saunders, PA, USA 671-713 (1995).
26. Luo D, Yin H, Xili L, Song J, Wang Z. The efficacy of Japanese encephalitis vaccine in Henan, China: a case-control study. Southeast Asian J. Trop. Med. Public Health 25(4), 643-646 (1994).
27. Hennessy S, Zehngle L, Tsai T et al. Effectiveness of live-attenuated Japanese encephalitis vaccine (SA 14-14-2), a case control study. Lancet 347, 1583-1586 (1996).
28. Steinhoff M. Japanese encephalitis: a Chinese solution? Lancet 347, 1570-1571 (1996).
29. Poland J, Cropp C, Craven R, Monath T. Evaluation of the potency and safety of inactivated Japanese encephalitis vaccine in US inhabitants. J. Infect. Dis. 161, 878-882 (1990).
30. Sanchez J, Hoke C, McCowan J. Further experience with Japanese encephalitis vaccine. Lancet 335, 972-973 (1990).
31. Japanese encephalitis vaccine and adverse effects among travelers. Can. Dis. Wkly Rep. 17, 173-177 (1991).
32. Berg SW, Mitchell BS, Hanson RK et al. Systemic reactions in U.S. Marine Corps personnel who received Japanese encephalitis vaccine. Clin. Infect. Dis. 24, 265-266 (1997).
33. Ohtaki E, Murakami Y, Komori H, Yamashita Y, Matsuishi T. Acute disseminated encephalomyelitis after Japanese B encephalitis vaccination. Pediatr. Neurol. 8(2), 137-139 (1992).
34. Andersen MM, Ronne T. Side-effects with Japanese encephalitis vaccine [letter]. Lancet 337(8748), 1044 (1991).
35. Ruff TA, Eisen D, Fuller A, Kass R. Adverse reactions to Japanese encephalitis vaccine [letter]. Lancet 338(8771), 881-882 (1991).
36. Nothdurft HD, Jelinek T, Marschang A, Maiwald H, Kapaun A, Löscher T. Adverse reactions to Japanese encephalitis vaccine in German travelers. J. Infect. 32, 119-122 (1996).
37. Tsai TF. New initiatives for the control of Japanese encephalitis by vaccination: minutes of a WHO/CVI Meeting, Bangkok, Thailand, 13-15 October 1998. Vaccine 18(Suppl. 2), 1-25 (2000).
38. Liu ZL, Hennessy S, Strom BL et al. Short-term safety of live attenuated Japanese encephalitis vaccine (SA14-14-2), results of a randomized trial with 26,239 subjects. J. Infect. Dis. 176, 1366-1369 (1997).
39. Tauber E, Dewasthaly S. Japanese encephalitis vaccines - needs, flaws and achievements. Biol. Chem. (2008) (Epub ahead of print).
40. Tauber E, Kollaritsch H, Korinek M et al. Safety and immunogenicity of a Vero-cell-derived, inactivated Japanese encephalitis vaccine: a non-inferiority, Phase III, randomised controlled trial. Lancet 370, 1847-1853 (2007).
41. Guirakhoo F, Zhang ZX, Chambers TJ et al. Immunogenicity, genetic stability, and protective efficacy of a recombinant, chimeric yellow fever-Japanese encephalitis virus (ChimeriVax-JE) as a live, attenuated vaccine candidate against Japanese encephalitis. Virology 257, 363-372 (1999).
42. Monath TP, Soike K, Levenbook I et al. Recombinant, chimaeric live, attenuated vaccine (ChimeriVax) incorporating the envelope genes of Japanese encephalitis (SA14-14-2) virus and the capsid and nonstructural genes of yellow fever (17D) virus is safe, immunogenic and protective in non-human primates. Vaccine 17, 1869-1882 (1999).
43. Monath TP, McCarthy K, Bedford P et al. Clinical proof of principle for ChimeriVax: recombinant live, attenuated vaccines against flavivirus infections. Vaccine 20, 1004-1018 (2002).
44. Monath TP, Guirakhoo F, Nichols R et al. Chimeric live, attenuated vaccine against Japanese encephalitis (ChimeriVax-JE), Phase 2 clinical trials for safety and immunogenicity, effect of vaccine dose and schedule, and memory response to challenge with inactivated Japanese encephalitis antigen. J. Infect. Dis. 188, 1213-1230 (2003).
45. Global Advisory Committee on Vaccine Safety. Wkly Epidemiol. Rec. 80, 241-248 (2005) www.who.int/vaccine_safety/topics/japanese_encephalitis/ mouse_brain_derived/en/index.html